Gilead announced it is voluntarily withdrawing Zydelig (idelalisib) for two blood cancer indications: relapsed follicular B-cell non-Hodgkin lymphoma (FL) and relapsed small lymphocytic leukemia (SLL). …
Kura Oncology announced the U.S. FDA has lifted the partial clinical hold on the KOMET-001 Phase 1b study of KO-539 in patients with relapsed or…
Oncopeptides announced data from the phase 3 randomized, head-to-head OCEAN study have been published in The Lancet Hematology. The study evaluated the efficacy and safety of…
IMV Inc. announced the first patient was dosed in the phase 2b VITALIZE clinical trial. VITALIZE is evaluating IMV’s lead compound, maveropepimut-S (MVP-S; formerly DPX-Survivac)…
BioMarin announced positive results from its ongoing global Phase 3 GENEr8-1 study evaluating valoctocogene roxaparvovec, an investigational gene therapy for the treatment of adults with…
Please confirm you want to block this member.
You will no longer be able to:
Please note: This action will also remove this member from your connections and send a report to the site admin. Please allow a few minutes for this process to complete.
